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Abstract
Background: Previous studies have shown the occurrence of actinin-3 deficiency in the presence of the R577X
polymorphism in the ACTN3 gene. Our hypothesis is that this deficiency, by interfering with the function of skeletal
muscle fiber, can result in a worse prognosis in patients with chronic heart failure.
Methods: A prospective cohort study was conducted from 2002 to 2004. The eligibility criteria included diagnosis
of chronic heart failure stage C from different etiologies. We excluded all patients with concomitant disease that
could be related to poor prognosis. ACTN3 rs1815739 (R577X) polymorphism was detected by high resolution
melting analysis. Survival curves were calculated with the Kaplan-Meier method and evaluated with the log-rank
statistic. The relationship between the baseline variables and the composite end-point of all-cause death was
assessed using a Cox proportional hazards survival model.
Results: A total of 463 patients were included in this study. The frequency of the ACTN3 577X variant allele was
39.0%. The LVEF mean was 45.6 ± 18.7% and the most common etiology of this study was hypertensive. After a
follow-up of five years, 239 (51.6%) patients met the pre-defined endpoint. Survival curves showed higher mortality
in patients carrying RX or XX genotypes compared with patients carrying RR genotype (p = 0.01).
Conclusion: R577X polymorphism in the ACTN3 gene was independently associated with worse survival in patients
with chronic heart failure. Further studies are necessary to ensure its use as a marker of prognosis for this syndrome.
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Background
Despite advances in the treatment of heart failure (HF)
over the past few years, the understanding of disease
mechanisms and prognosis still needs further investiga-
tion. The sequencing of the human genome and the
resulting advances in molecular biology have opened
new horizons since new prognostic biomarkers can serve
as a good guide in the understanding and treatment of
this complex disease [1].
It has been widely suggested that, although HF pa-
tients exhibit an abnormal cardiac output response to
exercise, peripheral factors, mainly located in skeletal
muscle, are the main determinants of low exercise toler-
ance in these patients and therefore involved in its prog-
nosis [2]. However, despite the association between
exercise capacity and prognosis of heart failure being
well established, the mechanisms of this interaction re-
main to be better understood.
In skeletal muscle, the main protein components of
the sarcomeric Z line are the alfa-actinins. In the heart
and oxidative skeletal muscle fibers, the predominant
expressed isoform is alfa-actinin-2 and in fast skeletal
muscle fibers is alfa-actinin-3 (ACTN3) [3]. The ACTN3
gene, located on 11q13.1, is expressed only in fast twitch
fibers, which trigger faster and generate more force than
alfa-actinin-2. The R577X polymorphism (rs1815739)
has been identified in the ACTN3 gene and it results in
a complete loss of the actinin-3 protein in XX homozy-
gotes and partial loss in heterozygote carriers [4].
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In this scenario, the main aim of this study was to as-
sess whether ACTN3 R577X polymorphism is associated
with mortality in heart failure patients.
Methods
Patient population
A prospective cohort study was conducted from 2002 to
2004 and included heart failure patients from Heart In-
stitute of University of São Paulo Medical School, São
Paulo, Brazil. The endpoint defined for this study was
all-cause death. Follow-up by medical attempts or by
telephone contact was performed each year until 2009.
The study protocol was approved by the Ethics Commit-
tee from Hospital das Clinicas (CAPPesq) and all par-
ticipants provided their written informed consent to
participate in this study [5].
The eligibility criteria was described previously [5]. Pa-
tients were enrolled when the presence of symptomatic
heart failure (stage C) was clinically diagnosed, functional
class III-IV and age over 18 years. Different etiologies were
included. Ischemic cardiomyopathy was defined when a
clear history of previous myocardial infarction without
other cause of left ventricular dysfunction or through cor-
onary angiography. Ischemic cardiomyopathy was also ex-
cluded for all patients with diagnosis of idiopathic dilated
cardiomyopathy through coronary angiography. Patients
with prior myocardial infarction (<3 months), unstable an-
gina, hypertrophic cardiomyopathy, valve heart disease
candidates to surgical treatment, obstructive pulmonary
disease, severe renal or hepatic dysfunction, current his-
tory of cancer, severe peripheral arterial disease, cerebro-
vascular disease and active infection were excluded.
Genotyping
Genomic DNA from subjects was extracted from periph-
eral blood following standard salting-out procedure.
Genotypes for the ACTN3 rs1815739 (R577X) poly-
morphism were detected by polymerase chain reaction
(PCR) followed by high resolution melting (HRM) ana-
lysis with the Rotor Gene 6000® instrument (Qiagen,
Courtaboeuf, France) [6]. Amplification of the fragments
was performed using the primer sense 5'-TCAGTTCA
AGGCAACACTGC-3' and antisense 5'-CTTCTGGA
TCTCACCCTGGA-3'. A 35-cycle PCR with addition of
fluorescent DNA-intercalating SYTO9® (1.5 μM; Invitro-
gen, Carlsbad, USA) was carried out with the following
conditions: denaturation of the template DNA for first
cycle of 94°C for 120 s, denaturation of 94°C for 20 s,
annealing of 60°C for 20 s, and extension of 72°C for
20 s. In the HRM phase, Rotor Gene 6000® (Qiagen,
Courtaboeuf, France) measured the fluorescence in each
0.1°C temperature increase in the range of 70-94°C.
Melting curves were generated by the decrease in fluor-
escence with the increase in the temperature; nucleotide
changes resulting from different curve patterns were an-
alyzed and genotyped. Samples of the three observed
curves were sequenced (ABI 3500XL Sequencer®, Ap-
plied Biosystems, Foster City, CA, USA) to confirm the
genotypes indicated by HRM. The two methods gave
identical results and, wild-type, heterozygous and homo-
zygous genotypes for the ACTN3 rs1815739 577X allele
could be easily discernible by HRM analysis [7].
Statistical analysis
Categorical variables were presented as percentage and
continuous variables were presented as mean ± standard
deviation. Demographic, biochemical, echocardiographic,
and clinical data were analyzed using Student’s t test for
continuous variables and the Chi-square test or Fisher’s
test for categorical variables. Survival curves were con-
structed with the Kaplan–Meier method and differences
between the curves were evaluated with the log-rank
statistic. Cox proportional hazard model was performed
to identify hazard ratios (HR) due to ACTN3 polymorph-
ism for the endpoint event, adjusted for age, gender, body
mass index, ethnicity, left ventricular ejection fraction
(LVEF), etiology (Chagasic was used as the reference cat-
egory due to its worse prognostic), hemoglobin, and cre-
atinine. These covariates were added in the model and
were based on their clinical relevance regarding to heart
failure. Our sample size provides 80% power to detect an
association with the endpoint event with an effect size
of 1.4 for the ACTN3 R577X polymorphism. Hardy-
Weinberg equilibrium analysis was estimated by the
Chi-square test. All statistical analyses were carried out
using SPSS software (version 16.0, IBM, New York, NY),
with the level of significance set at p <0.05.
Results
Of the 463 patients (mean age 58 ± 14), 283 (61.1%) were
male and 345 (74.5%) were Whites. The LVEF mean was
46 ± 19% and the most frequent etiologies were hyper-
tensive, ischemic, and valve diseases, with frequencies of
28.9%, 28.7% and 15.3%, respectively. After a follow-up
of five years, 239 (51.6%) patients met the pre-defined
study endpoint, the dropout was of 22.0% (n = 102), and
the mean follow-up was of 1,152 days.
The frequency of the ACTN3 577X variant allele was
39.0% and the distribution of the genotypes was 15.6%
(n = 72) for homozygous, 46.0% (n = 213) for heterozy-
gous and 38.4% (n = 178) for wild-type genotype. The
genotypic distribution for the ACTN3 R577X poly-
morphism was in accordance with the Hardy–Weinberg
equilibrium (X2 = 0.38, p = 0.53).
Table 1 shows baseline demographic, biochemical, echo-
cardiographic, and clinical characteristics according to
ACTN3 R577X polymorphism of the patients with heart
failure. These variables did not present significant difference
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according to genotypes. Figure 1 shows survival curves
with higher mortality in patients carrying RX or XX geno-
types compared with patients carrying RR genotype (p =
0.01). Furthermore, in a Cox proportional hazards survival
model, the presence of the RX or XX genotypes in pa-
tients with heart failure was independently associated with
higher hazard ratio compared with carriers of RR geno-
type (HR 1.72, 95% CI 1.14-2.62, p = 0.01) (Table 2), ad-
justed for covariates. Hemoglobin, creatinine, LVEF, and
hypertensive etiology were also significant factors in the
model.
Discussion
Our findings suggest that heart failure patients carrying
X allele of the ACTN3 R577X polymorphism had signifi-
cantly shorter survival time compared with patients with
the RR genotype and the presence of the X allele con-
ferred a worse prognosis. Known factors of worse prog-
nosis in HF were also significant in our model as levels
of creatinine, hemoglobin and LVEF.
Table 1 Baseline demographic, biochemical,
echocardiographic, and clinical characteristics according to
ACTN3 R577X polymorphism of the patients with heart
failure
RR (n = 178) RX + XX
(n = 285)
p value
Gender (male), % 64.6 58.9 0.22
Age, years 57 ± 14 58 ± 14 0.27
Body mass index, kg/m2 26 ± 5 25 ± 5 0.23
Ethnicity (Whites), % 68.5 78.2 0.09
Heart failure etiology, %
Chagasic 9.6 11.9
Idiopathic 9.6 10.5
Hypertensive 35.4 24.9 0.29
Ischemic 25.3 30.9
Valve disease 14.5 15.8
Other 5.6 6.0
Hypertension, % 62.4 62.8 0.92
Diabetes, % 25.3 25.6 0.93
Current smoker, % 12.4 7.0 0.06
Total cholesterol, mg/dL 193 ± 49 190 ± 52 0.57
LDL-C, mg/dL 123 ± 38 119 ± 44 0.34
HDL-C, mg/dL 46 ± 15 45 ± 15 0.69
Triglycerides, mg/dL 121 ± 68 123 ± 6.6 0.75
Glycemia, mg/dL 115 ± 38 109 ± 49 0.27
Creatinine, mg/dL 1.4 ± 0.8 1.4 ± 0.7 0.92
Frequency of death, % 46.6 54.7 0.08
Systolic blood pressure, mmHg 123 ± 33 121 ± 30 0.48
Diastolic blood pressure, mmHg 78 ± 20 75 ± 17 0.15
Heart rate, ppm 80 ± 14 79 ± 12 0.31
LVEF, % 46 ± 18 45 ± 19 0.71
LVM, g 259 ± 98 245 ± 83 0.12
LVEDD, mm 62 ± 12 62 ± 11 0.97
LVESD, mm 49 ± 15 49 ± 14 0.77
LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein
cholesterol; LVEF: Left ventricular ejection fraction; LVM: Left ventricular mass;
LVEDD: Left ventricular end-diastolic diameter; LVESD: Left ventricular
end-systolic diameter.
Figure 1 Survival curves according to ACTN3 R577X polymorphism
of the patients with heart failure.
Table 2 Cox proportional-hazards model for mortality in
patients with heart failure
Variables HR 95% CI p value
RX or XX genotypes for the ACTN3 R577X 1.72 1.14-2.62 0.01
Gender (male) 1.19 0.78-1.81 0.42
Age (years) 1.00 0.98-1.02 0.70
Body mass index (kg/m2) 0.99 0.95-1.04 0.93
Ethnicity (White vs Non-White) 1.24 0.78-1.94 0.36
Hemoglobin (g/dL) 0.87 0.79-0.94 0.002
Creatinine (mg/dL) 2.16 1.69-2.76 0.001
LVEF (%) 0.98 0.97-0.99 0.02
Etiology
Chagasic (reference) 1.00
Idiopathic 0.58 0.28-1.21 0.15
Hypertensive 0.50 0.26-0.97 0.04
Ischemic 0.74 0.42-1.32 0.31
Valve disease 0.70 0.35-1.40 0.32
HR: Hazard ratio; LVEF: Left ventricular ejection fraction.
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In this study, hypertensive etiology conferred a better
prognosis when compared with other causes of HF.
However, other authors have already associated different
etiologies with prognosis. Felker et al. showed a better
prognosis in patients with peripartum cardiomyopathy
while a worse prognosis has been demonstrated in pa-
tients with cardiomyopathy due to infiltrative myocardial
diseases, HIV infection, or doxorubicin therapy [8].
Nevertheless Ochiai et al. have shown that Chagas dis-
ease predicted low cardiac output in decompensated se-
vere heart failure and was associated with high levels of
BNP and a worse prognosis, independently from lower
ejection fraction [9]. But, these findings on HF prognosis
scenario need further investigation.
This is the first study to investigate the possible associ-
ation of the ACTN3 gene with the prognosis of heart
failure. Previous studies have associated this gene with
human physical performance and elite athletic perform-
ance [10-13]. The functions of actinin-3 are likely to in-
clude a structural role in the maintenance of muscle
mechanical integrity and other functions related to
muscle signaling and metabolism and ACTN3 R577X
polymorphism leads to its deficiency [14]. Some authors
showed the frequency of R wild-type allele was higher in
sprint and power athletes who specifically require opti-
mal fast fiber performance, while the X variant allele was
more frequent in endurance athletes who rely predomin-
antly on slow muscle fibers [15]. Additionally, a recent
systematic review and meta-analysis brought a stronger
evidence of the influence of the genetic profile with
physical performance in athletes with positive associ-
ation between ACTN3 R allele and power events [16].
Furthermore R577X has been studied in the general
population and it has been reported as one of many gen-
etic factors that may influence muscle function [13]. Pa-
tients with chronic HF often report skeletal muscle
weakness [17]; however, its mechanisms have not been
clearly defined. Some authors consider that contractility
is altered because of intracellular changes of Ca2+ me-
tabolism [2], while Sullivan et al. demonstrated a de-
crease in slow twitch type I fibers, and a higher
percentage of type IIb fast twitch fibers in chronic HF
patients [18].
The recent HF ACTION trial demonstrated exercise
to be associated with a significant reduction in all cause
and cardiovascular mortality as well as hospital admis-
sions [19]. The deficient muscle fiber type II in X allele
carriers could justify low functional capacity and conse-
quent worsening of survival.
The limitations of our study are the complex interact-
ing factors that influence muscle performance. It is diffi-
cult to decide whether muscle function altered by
genetic factors and training state could influence survival
in chronic HF. Moreover we did not evaluate the
physical capacity and muscular strength for more accur-
ate testing in these patients. Thus, this study serves to
generate hypotheses and requires further studies to con-
firm the possible interactions of gene-outcome in HF
patients. In addition, we suggested that the R577X poly-
morphism might be used as a prognostic marker in heart
failure. However, validation in a second population and
analysis of analytical parameters of the biomarker are
needed.
Conclusion
Our study suggested that R577X polymorphism in the
ACTN3 gene modulates survival and could be used, in
the future, as a prognostic marker in heart failure.
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